<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961363</url>
  </required_header>
  <id_info>
    <org_study_id>200904052M</org_study_id>
    <nct_id>NCT00961363</nct_id>
  </id_info>
  <brief_title>Effect of Sitagliptin in Impaired Glucose Tolerance</brief_title>
  <official_title>The Effect of Sitagliptin on Postprandial Glycemia and Endothelial Function in Chinese Subjects With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of sitagliptin 100 mg every
      day (q.d.) in improving hyperglycemia and endothelial dysfunction in subjects with impaired
      glucose tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in fasting and post-load plasma glucose levels during OGTT</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes in endothelial function, measured by circulating adhesion molecules</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the changes in beta cell functions derived from the glucose/insulin levels during OGTT</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety and the tolerability of sitagliptin, including clinical and laboratory adverse experiences, laboratory values, weight, and vital signs.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>sitagliptin 100 mg per day</description>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chinese subjects aged 40-65 years with fasting plasma glucose &lt; 100 mg/dL and OGTT
             2-hour glucose 140-199 mg/dL.

          2. Subjects are judged to be in otherwise general good health based on medical history,
             physical examination, and routine laboratory tests.

          3. Subject has an understanding of the study procedures, alternative treatments available
             and risk involved with the study, and voluntarily agrees to participate by giving
             written informed consent.

          4. Non-sterilized premenopausal female agrees to receive pregnancy test to confirm the
             non-pregnancy status and use adequate contraceptive methods to prevent pregnancy
             during the study period. Patient status should be confirmed by pregnancy test before
             enrollment.

        Exclusion Criteria:

          1. Evidence of diabetes (FPG&gt; 125 mg/dL, or OGTT 2-hour glucose&gt;=200 mg/dL, or current
             use of an anti-diabetic agents, except for history of gestational diabetes).

          2. History of intolerance or hypersensitivity or contraindication as mentioned in the
             approved package insert (appendix).

          3. Patient has any of the following disorders within the past 6 months: acute coronary
             syndrome (e.g., MI or unstable angina), coronary artery intervention (e.g., CABG or
             PTCA), stroke or transient ischemic neurological disorder.

          4. Patient has new or worsening signs or symptoms of coronary heart disease within the
             past 3 months.

          5. Patient has a BMI &gt; 40 kg/m2.

          6. Patient is on or likely to require more than 14 consecutive days or repeated courses
             of pharmacologic doses of corticosteroids. Note: inhaled, nasal, and topical
             corticosteroids are permitted.

          7. Patient is on or likely to require treatment with immunosuppressive agents (e.g.,
             cyclosporine, methotrexate).

          8. Advanced renal insufficiency (estimated creatinine clearance &lt; 50 ml/min).

          9. Severe hepatic insufficiency (Child-Pugh score &gt; 9, see Appendix).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee-Ming Chuang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee-Ming Chuang, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65038</phone_ext>
    <email>leeming@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee-Ming Chuang, MD, PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65038</phone_ext>
      <email>leeming@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Lee-Ming Chuang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Yuan Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Ju Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Hsiung Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shyang-Rong Shih, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tien-Jyun Chang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaw-Shiun Tsai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>March 19, 2010</last_update_submitted>
  <last_update_submitted_qc>March 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Lee-Ming Chuang</name_title>
    <organization>National Taiwan Univerisity Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

